Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have been assigned a consensus rating of “Moderate Buy” from the fifteen analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $60.0833.

Several research analysts have recently weighed in on the stock. HC Wainwright decreased their price target on shares of Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating on the stock in a report on Tuesday, December 2nd. Wedbush restated an “outperform” rating and set a $45.00 target price (down from $76.00) on shares of Janux Therapeutics in a research report on Tuesday, December 2nd. UBS Group restated a “buy” rating and issued a $57.00 target price on shares of Janux Therapeutics in a research note on Tuesday, December 2nd. Stifel Nicolaus lowered their price target on Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a report on Tuesday, December 2nd. Finally, Wall Street Zen raised Janux Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th.

Insider Activity

In related news, insider Charles M. Winter sold 2,401 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $32,965.73. Following the transaction, the insider directly owned 77,721 shares of the company’s stock, valued at approximately $1,067,109.33. This trade represents a 3.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Zachariah Mciver sold 2,714 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total value of $37,263.22. Following the completion of the sale, the insider directly owned 23,286 shares of the company’s stock, valued at approximately $319,716.78. This represents a 10.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 25,699 shares of company stock valued at $471,235. 8.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in JANX. Osaic Holdings Inc. lifted its holdings in shares of Janux Therapeutics by 704.6% in the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after acquiring an additional 3,037 shares during the last quarter. Virtus Investment Advisers LLC raised its position in Janux Therapeutics by 37.9% in the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after purchasing an additional 1,011 shares during the period. Tower Research Capital LLC TRC lifted its stake in Janux Therapeutics by 175.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after purchasing an additional 2,502 shares during the last quarter. Ameritas Investment Partners Inc. boosted its position in Janux Therapeutics by 25.6% during the second quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock valued at $93,000 after buying an additional 820 shares during the period. Finally, Winthrop Capital Management LLC bought a new position in shares of Janux Therapeutics during the third quarter valued at about $106,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Trading Down 0.9%

Shares of Janux Therapeutics stock opened at $13.71 on Friday. The company’s 50-day moving average price is $16.80 and its 200-day moving average price is $22.34. Janux Therapeutics has a 12-month low of $12.80 and a 12-month high of $46.10. The company has a market cap of $824.66 million, a price-to-earnings ratio of -8.16 and a beta of 2.88.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.21. The firm had revenue of $10.00 million for the quarter, compared to the consensus estimate of $3.07 million. On average, sell-side analysts predict that Janux Therapeutics will post -1.38 earnings per share for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.